Strong quarterly financial results and corporate restructuring plans have driven investor optimism for the drugmaker, with the stock rebounding 67% from its 52-week low. Operating growth was largely propelled by a significant expansion in overseas markets alongside steady domestic sales. Major brokerages have responded by maintaining bullish recommendations and lifting their price targets, citing upcoming international drug rollouts. Under its strategic "One Emcure" initiative, the company also intends to merge subsidiaries Zuventus and Emcutix into the holding company to capture backend operational synergies.
Key points
Jefferies raised its target price on the stock to ₹2,500 while maintaining a Buy rating d…: Jefferies raised its target price on the stock to ₹2,500 while maintaining a Buy rating due to European product rollouts.
Kotak Institutional Equities kept a Buy rating with a target price of ₹2,450, projecting…: Kotak Institutional Equities kept a Buy rating with a target price of ₹2,450, projecting a 19% annual earnings per share growth from FY26 to FY29.
Management plans to merge Zuventus and Emcutix into the parent company under the One Emcu…: Management plans to merge Zuventus and Emcutix into the parent company under the One Emcure initiative to streamline operational efficiency.
Sources checked by our analysis pipeline: 1
Shares of Emcure Pharmaceuticals jumped 10% to ₹2,180.80 on Wednesday, November 4, scaling a record high after gaining 5% in the previous session. The stock has rallied 16% in just two trading sessions following the pharmaceutical company's strong September quarter results (Q2FY27).
Robust revenue and profit growth, improving business prospects across domestic and international markets, and positive brokerage commentary have strengthened investor sentiment towards the stock.
Emcure Pharma shares touched a record high of ₹2,180.80 apiece on the BSE. The stock has now gained 67% from its 52-week low of ₹1,307.50, recorded in November 2025.
The stock has delivered strong returns across time periods, rising 12% in one month, 10% in three months, 21% in six months and 64% over the past year.
Emcure Pharmaceuticals reported a 29.3% year-on-year (YoY) increase in adjusted profit after tax (PAT) to ₹325.1 crore in Q2FY27 compared with ₹251.4 crore in the corresponding quarter last year.
Revenue from operations rose 24.3% YoY to ₹2,820.5 crore from ₹2,269.8 crore in Q2FY26. EBITDA increased 30.9% to ₹574.8 crore, against ₹439.1 crore a year ago. EBITDA margin…
Authorities allege that three trading accounts were coordinated over a 22-month period to artificially inflate the share price of the Catalist-listed food court operator. The case also involves separate allegations of evidence tampering through deleted communications. These severe regulatory offenses carry substantial prison terms and fines upon conviction.
The enterprise software firm achieved a key milestone during the second quarter by pushing quarterly operational income past the $100 million mark for the first time. Heavy adoption across the healthcare and financial sectors fueled the bottom-line expansion, alongside widening operational margins. Even with the market's enthusiastic reaction to the quarterly numbers, the equity continues to sit notably below its record high set earlier this year.
Central bank interventions aimed at curbing currency speculation have caused market participants to dramatically pull back from forward contracts. While these stringent measures helped the rupee rebound from near-record lows, the resulting spike in hedging costs has paralyzed activity and sparked outflows from domestic bonds. Policymakers now face the delicate task of balancing currency defense against broader strains from expensive oil imports.